Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.820
-0.220 (-4.37%)
At close: Sep 4, 2026, 4:00 PM EDT
4.845
+0.025 (0.52%)
After-hours: Sep 4, 2026, 7:54 PM EDT
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
57
Market Cap
311.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Orchestra BioMed Holdings | 31.98M |
| Pyxis Oncology | 11.04M |
| Fate Therapeutics | 6.49M |
| Upstream Bio | 3.16M |
IMRX News
- 3 days ago - Immuneering to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Immuneering says FDA approval of pancreatic cancer treatment ‘good news’ - TheFly
- 11 days ago - Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - GlobeNewsWire
- 4 weeks ago - Immuneering initiated with a Buy at H.C. Wainwright - TheFly
- 4 weeks ago - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - Immuneering Earnings release: Q2 2026 - Filings
- 4 weeks ago - Immuneering Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Immuneering publishes preclinical data on atebimetinib in Cancer Research - TheFly